Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871776 · ClinicalTrials.gov registry record · NA
Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
A NA study of Covid19 and Vaccine Refusal, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 3,671
- Enrollment target
- 1
- Study location
NCT04871776 is a NA study of Covid19 and Vaccine Refusal that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 3,671 participants, above the 2,663-participant average among 94 other Covid19 trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04871776, a NA study of Covid19 and Vaccine Refusal, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,671 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Messaging informed by construal level theory
Study Locations (1)
Massachusetts
- Mass General Brigham - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,671 participants |
| Start Date | 2022-02-18 |
| Est. Completion | 2022-08-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04871776
The ClinicalTrials.gov registry entry for NCT04871776 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3,671 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,663-participant average among 94 other Covid19 trials with a reported enrollment target (38% higher). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT04871776 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04871776 about?
NCT04871776 is a clinical study titled "Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19". This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upco...
What is the current status of trial NCT04871776?
This trial is currently completed. It is a NA study. The enrollment target is 3,671 participants. The study started on 2022-02-18. Estimated completion is 2022-08-17.
What conditions does trial NCT04871776 study?
This clinical trial studies the following conditions: Covid19, Vaccine Refusal.
What interventions are being tested in trial NCT04871776?
The interventions under investigation include: Usual Care (BEHAVIORAL), Messaging informed by construal level theory (BEHAVIORAL).
Who is sponsoring clinical trial NCT04871776?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04871776 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Multimodal Parent-focused Intervention for Vulnerable Populations in the Bronx
RECRUITING · NA
-
Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks
ACTIVE NOT RECRUITING · NA
-
Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
ACTIVE NOT RECRUITING · NA
-
A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion
COMPLETED · NA
-
Implementation of COVID-19 Testing Strategies in Community Health Centers
COMPLETED · NA
-
Minnesota COVID-19 Testing Project
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.